secwatch.observer — SEC 8-K summary
======================================

Issuer:     OMEROS CORP (OMER)
CIK:        0001285819
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001437749-25-014815
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omeros announces FDA accepts BLA resubmission for narsoplimab in TA-TMA; PDUFA late Sept 2025
--------------------------------------------------------------------------------

- FDA accepted Class 2 resubmission of BLA for narsoplimab for TA-TMA; PDUFA target action date late September 2025.
- Resubmission includes survival analyses comparing narsoplimab-treated patients to external control, showing statistically significant improvement.
- Also includes data from expanded access program in adult and pediatric TA-TMA patients.
- Omeros is preparing MAA for submission to European Medicines Agency later this quarter.
- Company responding to FDA information requests; expects interactive review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285819/000143774925014815/0001437749-25-014815-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285819/000143774925014815/omer20250506_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-014815

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer